Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 3;54(1):147-148.
doi: 10.1016/j.jmii.2020.09.007. Online ahead of print.

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19

Tzu-Yi Chuang  1 , Ming-Han Tsai  2 , Lit-Min Wu  3 , Sung-Jung Ho  4 , Pu-Sheng Yeh  4 , Yi-Lien Liu  5 , Hung-Jen Fred Yang  6
Affiliations

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19

Tzu-Yi Chuang et al. J Microbiol Immunol Infect. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serial chest radiographs revealed changes from bilateral subpleural infiltration (A) to bilateral subpleural patch of consolidation with ARDS (B), then turned to bilateral subpleural nodular infiltration (C), and chest CT scan showed subpleural fibrosis (D).
See this image and copyright information in PMC

References

    1. Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. - DOI - PMC - PubMed
    1. Toniati P., Piva S., Cattalini M., Garrafa E., Regola F., Castelli F. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia. Italy Autoimmun Rev. 2020 May 3:102568. doi: 10.1016/j.autrev.2020.102568. - DOI - PMC - PubMed
    1. Drożdżal S., Rosik J., Lechowicz K., Machaj F., Kotfis K., Ghavami S. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updates. 2020 Jul 15;53:100719. doi: 10.1016/j.drup.2020.100719. - DOI - PMC - PubMed
    1. Antony S.J., Davis M.A., Davis M.G., Almaghlouth N.K., Guevara R., Omar F. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. J Med Virol. 2020 Jul 9 doi: 10.1002/jmv.26288. 10.1002/jmv.26288. - DOI - PMC - PubMed
    1. Jean S.S., Lee P.I., Hsueh P.R. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53:436–443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4. - DOI - PMC - PubMed